SMH ·general ·5 hours ago

‘Unviable’: 450,000 Australians to miss out on subsidised weight loss drug

Eli Lilly's decision not to subsidise its weight loss drug Mounjaro will leave 450,000 Australians without access to the medication. The Pharmaceutical Benefits Advisory Committee had recommended the drug for Type 2 diabetes patients, highlighting the need for better access to effective treatment options. The outcome may also hinder future subsidies for related conditions.

Summary by Glance · SMH

Next